New York State Common Retirement Fund boosted its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 27.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,616 shares of the company’s stock after buying an additional 23,316 shares during the period. New York State Common Retirement Fund’s holdings in Amneal Pharmaceuticals were worth $1,539,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Menta Capital LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at $403,000. SG Americas Securities LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at $192,000. Meeder Asset Management Inc. boosted its stake in shares of Amneal Pharmaceuticals by 785.6% in the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after purchasing an additional 10,347 shares in the last quarter. Norges Bank acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at $18,243,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Amneal Pharmaceuticals by 30.4% in the 4th quarter. Principal Financial Group Inc. now owns 16,485 shares of the company’s stock valued at $223,000 after purchasing an additional 3,843 shares in the last quarter. Hedge funds and other institutional investors own 36.05% of the company’s stock.

Several equities research analysts have recently commented on AMRX shares. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 target price on shares of Amneal Pharmaceuticals in a research note on Thursday, February 28th. Raymond James upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, May 21st. They noted that the move was a valuation call. Svb Leerink downgraded shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $16.00 to $12.00 in a research note on Friday, March 8th. BMO Capital Markets reduced their target price on shares of Amneal Pharmaceuticals from $14.00 to $13.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Finally, SunTrust Banks started coverage on shares of Amneal Pharmaceuticals in a research note on Tuesday, March 19th. They issued a “buy” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Amneal Pharmaceuticals has an average rating of “Hold” and a consensus target price of $16.73.

In other Amneal Pharmaceuticals news, SVP Joseph Todisco purchased 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average cost of $9.88 per share, with a total value of $148,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Pradeep Bhadauria purchased 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average cost of $8.48 per share, with a total value of $59,360.00. The disclosure for this purchase can be found here. Insiders purchased 41,000 shares of company stock valued at $387,300 over the last ninety days. 26.34% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals stock opened at $6.87 on Friday. The company has a debt-to-equity ratio of 3.44, a current ratio of 2.11 and a quick ratio of 1.37. Amneal Pharmaceuticals Inc has a 12-month low of $6.84 and a 12-month high of $24.48. The stock has a market capitalization of $2.05 billion, a P/E ratio of 7.23, a price-to-earnings-growth ratio of 0.45 and a beta of 1.63.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.07). Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The business had revenue of $446.00 million during the quarter, compared to the consensus estimate of $438.18 million. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. As a group, sell-side analysts predict that Amneal Pharmaceuticals Inc will post 0.91 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2019/06/15/new-york-state-common-retirement-fund-acquires-23316-shares-of-amneal-pharmaceuticals-inc-nyseamrx.html.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Story: What is total return in investing?

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.